Management of broncholithiasis.

Broncholithiasis is a condition in which calcified material has entered the tracheobronchial tree, at times causing airway obstruction and inflammation. Broncholiths generally originate as calcified material in mediastinal lymph nodes that subsequently erode into adjacent airways, often as a result of prior granulomatous infection. Disease manifestations range from asymptomatic stones in the airway to life-threatening complications, including massive hemoptysis and post-obstructive pneumonia. Radiographic imaging, particularly computed tomography scanning of the chest, is integral in the evaluation of suspected broncholithiasis and can be helpful to assess involvement of adjacent structures, including vasculature, prior to any planned intervention. Management strategies largely depend on the severity of disease. Observation is warranted in asymptomatic cases, while therapeutic bronchoscopy and surgical interventions may be necessary for cases involving complications. Bronchoscopic extraction is often feasible in cases in which the broncholith is freely mobile within the airway, whereas partially-embedded broncholiths represent additional challenges. Surgical intervention is indicated for advanced cases deemed not amenable to endoscopic management. Complex cases involving complications such as massive hemoptysis and/or bronchomediastinal fistula formation are best managed with a multidisciplinary approach, utilizing expertise from fields such as pulmonology, radiology, and thoracic surgery.

Malignant solitary fibrous tumour of the bronchus.

Solitary fibrous tumours most commonly present in the pleura, but have been reported in other extrapleural sites. We present a case of an elderly female who was found to have a malignant solitary fibrous tumour of the right upper lobe bronchus, treated with thoracoscopic lobectomy and bronchoplastic closure.

Comparison of pulmonary complications after nonmyeloablative and conventional allogeneic hematopoietic cell transplant.

Nonmyeloablative conditioning before allogeneic hematopoietic cell transplant (HCT) is an alternative to conventional conditioning in older patients and those with comorbidities. It is not known whether the decreased tissue injury associated with nonmyeloablative conditioning lowers the risk of pulmonary complications. The medical records of patients who underwent transplantation were reviewed and all pulmonary complications documented. Sixty-two consecutive patients with hematologic malignancies who underwent minimally intensive HCT (subjects) were compared to 48 consecutive patients who received conventional myeloablative allogeneic peripheral blood HCT (controls) over the same period at Indiana University Hospital. Pulmonary complications were categorized according to the type of complication and the time of onset after transplantation. Median follow-up times were similar between groups (P = .70). The study population (minimal intensity recipients) was older (P < .01), and the incidence of chronic graft-versus-host disease (cGVHD) was higher in subjects than controls (P = .02). Sixty-nine percent of subjects and 73% of controls developed pulmonary complications (P = .70). There was a trend in the minimally conditioned patients towards a lower incidence of pulmonary complications in older patients in the early posttransplantation period and a higher incidence of infectious pneumonias and bronchiolitis obliterans syndrome at later time points. The frequency of pulmonary complications seems to be similar after minimally intensive or myeloablative conditioning and allotransplantation. There was no difference in overall mortality or pulmonary-related mortality between the 2 groups.

Glomus tumor of the trachea.

INTRODUCTION: We describe a primary glomus tumor of the trachea. METHODS: A patient presented to our institution with a mid-tracheal mass. RESULTS: We performed a tracheal resection on this patient. CONCLUSION: The final pathology was consistent with glomus tumor of the trachea.

Nurse-administered propofol sedation: feasibility and safety in bronchoscopy.

BACKGROUND: Propofol is a fast-acting intravenous sedative that has advantages as a procedural sedative over traditional regimens. It has been shown to have a similar safety profile to traditional sedating medications in the setting of gastroenterologic endoscopy. Nurse-administered propofol sedation is given by a specially-trained nurse, without anesthesiologist involvement. OBJECTIVES: We have used nurse-administered propofol sedation in our bronchoscopy suite for several years. In this report, we summarize our experience with nurse-administered propofol sedation, and demonstrate it to be feasible and safe for bronchoscopic procedures. METHODS: Procedure reports and nursing notes for 588 bronchoscopic procedures performed between July 2006 and June 2008 were retrospectively reviewed. Patient demographics, procedure type and indication, procedure time, medication doses, and adverse events were noted and analyzed. RESULTS: Nurse-administered propofol sedation was used in 498/588 (85%) procedures. Patients utilizing nurse-administered propofol sedation had an average age of 53 years (range 18-86) with an average weight of 80 kg. 56% of the patients were male, and 57% of the procedures were performed on outpatients. Average procedure duration was 25 min (range 3-123). The average propofol dose was 3.13 mg/kg (range 0.12-20 mg/kg). Adverse events attributable to sedation were noted in 33 (6.6%) procedures. Of the 14 (2.8%) major adverse events (death, need for intubation, ICU stay, or hospitalization), only 6 (1.2%) were potentially attributable to the sedation regimen. There were 2 deaths, neither of which was related to sedation. CONCLUSIONS: Nurse-administered propofol sedation is a feasible and safe sedation method for bronchoscopic procedures.

Endobronchial ultrasound.

UNLABELLED: During flexible fiberoptic bronchoscopy (FB), a solitary pulmonary nodule (SPN) is sampled by means of transbronchial needle aspiration (TBNA), brush, or transbronchial lung biopsy under fluoroscopy; and mediastinal lymph nodes are sampled using "blind" TBNA. Endobronchial ultrasound (EBUS) was developed to help visualize the lesion at the time of biopsy in order to improve the diagnostic yield. METHODS: There are two types of EBUS techniques: using a radial probe (RP) with a rotating transducer at the distal tip, which produces a 360 degrees image to the long axis of the bronchoscope; and using an EBUS bronchoscope with a linear transducer at its distal tip, producing a 50 degrees image parallel to its long axis. RESULTS: In biopsies of SPNs < 2 cm using an RP, EBUS demonstrates a higher diagnostic yield than conventional FB techniques. With mediastinal and hilar nodal stations, except for the subcarina, EBUS shows a higher yield over blind TBNA. The current procedural terminology code for EBUS is 31620, a "ZZZ" code submitted in addition to other performed procedures (31622-31638). In 2007, an estimate of physician Medicare reimbursement for EBUS is $70.49. Reimbursement is locality dependent and based on economic-exchange conversion factors. Incorporating an ultrasound image into the report substantiates the use of this technique. LIMITATIONS: The physician must learn ultrasound image interpretation and the EBUS technique, and be skilled in TBNA. Maintaining competency requires frequent performance of EBUS. CONCLUSION: EBUS-directed biopsy improves the yield over conventional FB for SPNs < 2 cm and for most mediastinal or hilar nodal stations. This reduces the need to conduct additional diagnostic procedures.

Endobronchial electrosurgery: argon plasma coagulation and electrocautery.

Endobronchial electrosurgery is used to remove endobronchial lesions in the trachea and bronchi, using either a rigid or a flexible bronchoscope. The thermal property of electric current is used to destroy tissue or coagulate bleeding sites. Electrosurgery, electrocautery, electrotherapy, and surgical diathermy are terms often used when referring to the use of heat for tissue destruction. In this article, we specifically use the term electrocautery ( EC) to describe an electrosurgical technique that requires probe-to-tissue contact whereby the conduction of electric current ionizes air resulting in tissue destruction or hemostasis or both. In contrast, argon plasma coagulation (APC) is a relatively new electrosurgical method whereby argon gas is ionized by an electric current to create a noncontact, homogeneous "bridge" to target tissue for coagulation or ablation. Both EC and APC are effective in ablating and coagulating tissue. In this article, we further elucidate the basic principles of electrosurgery; indications, complications, and techniques associated with both EC and APC; and how they compare with other standard endobronchial interventions, including mechanical debridement, laser photoresection, cryotherapy, photodynamic therapy (PDT), and brachytherapy.

Diagnosis and treatment of early lung cancer: as it stands today.

Treatment of "early" stage lung cancer should offer the patient the best chance for cure. Disease-free survival after surgical resection of lung carcinoma in situ has been reported as over 90%. For "microinvasive" lung cancer it may be similar. After resection of stage IA non-small cell lung cancer, survival at 5 years is approximately 60 to 70%. If endoscopic or bronchoscopic treatments of early stage lung cancer can offer similar disease-free survival with less perioperative mortality, morbidity, and cost, then they may be alternative front-line therapies. Regardless of therapeutic choice, the initial hurdle is developing a practical detection method for early stage disease. This article reviews early stage lung cancer detection by fluorescence bronchoscopy and potential treatment by the endoscopic techniques of photodynamic therapy, brachytherapy, neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, electrocautery, and cryotherapy.

Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.

Prostate carcinoma presenting initially as multiple pulmonary nodules in an asymptomatic patient without previous prostate carcinoma is unusual. Whether the incidence of prostate carcinoma is significantly increased in patients treated previously for germ cell tumors is unclear. We report such a patient, who responded to combination androgen blockade therapy.